Abstract

COMPARATIVE STUDY OF DIFFERENT BLOOD PARAMETERS IN DIFFERENT TRANSFUSION DEPENDENT THALASSAEMIC PATIENTS WITH THALIDOMIDE AND RESVERATROL THERAPY

Anirban Roy Chowdhury*, Amit Chakravarty, Shakuntala Ghose and Sudipa Chakravarty

ABSTRACT

Recent molecular studies of fetal hemoglobin (HbF) regulation have shown promise for the development of clinical HbF inducers to be used in patients with β-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF, have been studied at past in β-thalassemia patient with limited success resulted no universally effective agents. Increased production of fetal hemoglobin (HbF) can ameliorate the severity of both β-thalassemia and sickle cell disease (SCD), the major disorders of β-hemoglobin. The defective production of the β-globin molecule in patients with β-thalassemia can be compensated for by an increase in the production of the β-like globin molecule, γ-globin, which pairs together with α-globin chains to form HbF. Here we examined the comparative clinical studies of Trans- Resveratrol and Thalidomide therapy of different CBC parameters of different transfusion dependent thalassaemic patients and we found the promising results of our study. Patients who, after more than six months of treatment, remained at the different level of transfusion dependency with extended transfusion intervals. The present study is to provide a resource that will be valuable for the design of future studies of HbF inducers in β-thalassemia.

Keywords: Resveratrol, Thalidomide, ?-thalassemia, HbF Inducer, Blood transfusion, CBC parameters.